OpenURL Connection Search

Select item for more details and to access through your institution.

The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
Published in:
International Journal of Laboratory Hematology, 2018, v. 40, n. 4, p. 442, doi. 10.1111/ijlh.12807
By:
- Feyen, L.;
- Jacquemin, M.;
- Vanassche, T.;
- Peerlinck, K.;
- Verhamme, P.;
- Toelen, J.;
- Schoeters, J.;
- Van Horenbeeck, I.;
- Vanlinthout, I.;
- Debasse, M.
Publication type:
Article
Correction to: Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
Published in:
2021
By:
- Unverdorben, M.;
- von Heymann, C.;
- Santamaria, A.;
- Saxena, M.;
- Vanassche, T.;
- Jin, J.;
- Laeis, P.;
- Wilkins, R.;
- Chen, C.;
- Colonna, P.
Publication type:
corrected article
Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
Published in:
2020
By:
- Unverdorben, M.;
- von Heymann, C.;
- Santamaria, A.;
- Saxena, M.;
- Vanassche, T.;
- Jin, J.;
- Laeis, P.;
- Wilkins, R.;
- Chen, C.;
- Colonna, P.
Publication type:
journal article
Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.
Published in:
Netherlands Heart Journal, 2021, v. 29, n. 3, p. 158, doi. 10.1007/s12471-020-01518-7
By:
- de Vries, T. A. C.;
- Hemels, M. E. W.;
- Cools, F.;
- Crijns, H. J. G. M.;
- Yperzeele, L.;
- Vanacker, P.;
- Blankoff, I.;
- Lancellotti, P.;
- Mairesse, G. H.;
- de Veer, A.;
- Casado Arroyo, R.;
- Catez, E.;
- de Pauw, M.;
- Vanassche, T.;
- de Asmundis, C.;
- Kirchhof, P.;
- De Caterina, R.;
- de Groot, J. R.
Publication type:
Article
Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Published in:
2020
By:
- Vanassche, T.;
- Engelen, M. M.;
- Van Thillo, Q.;
- Wauters, J.;
- Gunst, J.;
- Wouters, C.;
- Vandenbriele, C.;
- Rex, S.;
- Liesenborghs, L.;
- Wilmer, A.;
- Meersseman, P.;
- Van den Berghe, G.;
- Dauwe, D.;
- Verbeke, G.;
- Thomeer, M.;
- Fivez, T.;
- Mesotten, D.;
- Ruttens, D.;
- Heytens, L.;
- Dapper, I.
Publication type:
corrected article
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Published in:
2020
By:
- Vanassche, T.;
- Engelen, M. M.;
- Van Thillo, Q.;
- Wauters, J.;
- Gunst, J.;
- Wouters, C.;
- Vandenbriele, C.;
- Rex, S.;
- Liesenborghs, L.;
- Wilmer, A.;
- Meersseman, P.;
- Van den Berghe, G.;
- Dauwe, D.;
- Verbeke, G.;
- Thomeer, M.;
- Fivez, T.;
- Mesotten, D.;
- Ruttens, D.;
- Heytens, L.;
- Dapper, I.
Publication type:
journal article

Found: 6

The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.

Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.

Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.

A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.